CLINICAL TRIALS PROFILE FOR ROGAINE EXTRA STRENGTH (FOR MEN)
✉ Email this page to a colleague
All Clinical Trials for ROGAINE EXTRA STRENGTH (FOR MEN)
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01309191 ↗ | Microarray Analysis of Scalp Biopsies After Minoxidil Treatment | Completed | Kaiser Permanente | N/A | 2011-04-01 | The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia. |
| NCT01309191 ↗ | Microarray Analysis of Scalp Biopsies After Minoxidil Treatment | Completed | University of California, San Francisco | N/A | 2011-04-01 | The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia. |
| NCT01309191 ↗ | Microarray Analysis of Scalp Biopsies After Minoxidil Treatment | Completed | University Hospitals Cleveland Medical Center | N/A | 2011-04-01 | The purpose of this study is to determine whether Minoxidil treatment affects hair growth in patients with male pattern baldness or androgenetic alopecia. |
| NCT03488108 ↗ | Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women | Completed | Mayo Clinic | Phase 1/Phase 2 | 2017-01-23 | The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss. |
| NCT03852992 ↗ | Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia | Not yet recruiting | University of Minnesota | Phase 2 | 2021-09-01 | The objective of this study is to evaluate the safety and efficacy of fractionated ablative 10,600nm CO2 laser assisted delivery of 2% minoxidil solution in the treatment of MPHL. In this cohort study, patients will randomly be assigned stand-alone laser treatment, laser assisted drug delivery of minoxidil 2% solution, and laser assisted drug delivery of minoxidil 2% solution plus at home 5% minoxidil treatment. The primary endpoints will be to assess the change from baseline in investigator and subject Hair Growth Assessments (HGA), Hair Growth Index (HGI) and the Hair Growth Satisfaction Scale (HGSS) over 8-12 weeks in each of the three groups. The secondary endpoints will be expert assessment of hair density from baseline and evaluation of safety and adverse events, and pharmacokinetic (PK) data. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ROGAINE EXTRA STRENGTH (FOR MEN)
Condition Name
| Condition Name for ROGAINE EXTRA STRENGTH (FOR MEN) | |
| Intervention | Trials |
| Androgenetic Alopecia | 2 |
| Anatomic Stage III Breast Cancer AJCC v8 | 1 |
| Prognostic Stage I Breast Cancer AJCC v8 | 1 |
| Anatomic Stage IIIA Breast Cancer AJCC v8 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ROGAINE EXTRA STRENGTH (FOR MEN)
Trials by Country
Clinical Trial Progress for ROGAINE EXTRA STRENGTH (FOR MEN)
Clinical Trial Phase
Clinical Trial Sponsors for ROGAINE EXTRA STRENGTH (FOR MEN)
Sponsor Name
